Bioavailability, bioequivalence, and in vitro-in vivo correlation of oxybutynin transdermal patch in rabbits

被引:8
作者
Khire, Achyut [1 ]
Vavia, Pradeep [1 ]
机构
[1] Elite Status & Ctr Excellence Govt Maharashtra, Inst Chem Technol, Dept Pharmaceut Sci & Technol, Ctr Novel Drug Delivery Syst, Bombay 400019, Maharashtra, India
关键词
Transdermal; Oxybutynin; IVIVC; Pharmacokinetics; Convolution; EXTENDED-RELEASE FORMULATION; CORRELATION IVIVC MODEL; DRUG-DELIVERY; CONVOLUTION; PRINCIPLES; SYSTEMS; SKIN;
D O I
10.1007/s13346-013-0170-y
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
The first objective of the proposed research work includes comparative bioavailability and bioequivalence evaluation of oxybutynin transdermal patch with respect to different permeation enhancers. The second objective was to evaluate different in vitro methods along with synthetic membranes toward development of an in vitro-in vivo correlation. Oleic acid (fatty acid), Soluphor P (2-pyrrolidone, cosolvent), menthol (volatile oil), and dipropylene glycol (plasticizer) were selected as representatives from different classes of permeation enhancers. A random, crossover, single-dose pharmacokinetic study was carried out on male New Zealand white rabbits to determine bioavailability and bioequivalence. The obtained pharmacokinetic data were correlated with in vitro drug release using convolution-deconvolution approach. All developed formulations were found to be bioequivalent with respect to the marketed patch (Oxytrol (R)) on the basis of level of C-max, AUC(0-96), and AUC(total) (0.8-1.25). A biphasic linear correlation was obtained pertaining to differential diffusion behavior of the drug in vivo during the experimental timeframe. Because of close resemblance to skin, Cuprophan (R) membrane was found to be more suitable for developing an IVIVC than Millipore (R) membrane.
引用
收藏
页码:105 / 115
页数:11
相关论文
共 29 条
[1]  
[Anonymous], 2002, Dermatological and transdermal formulations
[2]   Direct, differential-equation-based in-vitro-in-vivo correlation (IVIVC) method [J].
Buchwald, P .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (04) :495-504
[3]   A time scaling approach to develop an in vitro-in vivo correlation (IVIVC) model using a convolution-based technique [J].
Costello, Cian ;
Rossenu, Stefaan ;
Vermeulen, An ;
Cleton, Adriaan ;
Dunne, Adrian .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2011, 38 (05) :519-539
[4]   Artificial neural networks applied to the in vitro in vivo correlation of an extended-release formulation: Initial trials and experience [J].
Dowell, JA ;
Hussain, A ;
Devane, J ;
Young, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (01) :154-160
[5]   A population approach to in vitro-in vivo correlation modelling for compounds with nonlinear kinetics [J].
Gaynor, Clare ;
Dunne, Adrian ;
Costello, Cian ;
Davis, John .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2011, 38 (03) :317-332
[6]   A 1-Step Bayesian Predictive Approach for Evaluating In Vitro In Vivo Correlation (IVIVC) [J].
Gould, A. Lawrence ;
Agrawal, Nancy G. B. ;
Goel, Thanh V. ;
Fitzpatrick, Shaun .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2009, 30 (07) :366-388
[7]  
Harushi M, 2007, BIOL PHARM BULL, V30, P955
[8]   Combined Models for Data from In Vitro-In Vivo Correlation Experiments [J].
Jacobs, Tom ;
Rossenu, Stefaan ;
Dunne, Adrian ;
Molenberghs, Geert ;
Straetemans, Roel ;
Bijnens, Luc .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (06) :1197-1211
[9]  
KAIHO F, 1987, CHEM PHARM BULL, V35, P2928
[10]   Level A in vitro-in vivo correlation (IVIVC) model with Bayesian approach to formulation series [J].
Kortejarvi, H. ;
Malkki, J. ;
Marvola, M. ;
Urtti, A. ;
Yliperttula, M. ;
Pajunen, P. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (07) :1595-1605